DKK664.4m market cap
DKK4.01 last close
BioPorto is a diagnostic company focused on the development and marketing antibodies and other products for research and diagnostics. This includes a portfolio of products marketed for research use and The NGAL Test, which the company has submitted to the FDA for the prediction of acute kidney injury.
Investment summary
BioPorto announced on 3 October 2018 that it had received feedback from the FDA on its outstanding 510(k) application for The NGAL Test for risk use with acute kidney injury (AKI). The agency said that additional data would be required to support a ‘rule-out’ claim (ie that the test can exclude the risk of AKI). The company is engaged in discussions with the agency and has revised its timeline: an FDA decision in mid-2019.
Y/E Dec |
Revenue (DKKm) |
EBITDA (DKKm) |
PBT (DKKm) |
EPS (ore) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2016A | 20.7 | (22.6) | (22.4) | (157.0) | N/A | N/A |
| 2017A | 25.2 | (33.1) | (33.7) | (203.0) | N/A | N/A |
| 2018E | 29.6 | (37.6) | (37.2) | (209.0) | N/A | N/A |
| 2019E | 34.7 | (17.7) | (17.0) | (91.0) | N/A | N/A |
| Last updated on 19/02/2019 | ||||||
Industry outlook
The current standard of care for detecting AKI is serum creatinine, which can take 24 hours or more to detect AKI and can only do so after significant kidney damage. NGAL promises to provide a quicker and more reliable test, allowing early intervention to preserve kidney function.
Last updated on 19/02/2019
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (DKKm) | 12.4 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Thomas Magnussen | Chairman |
| Peter Mørch Eriksen | CEO |
| Ole Larsen | CFO |
| Jan Kuhlmann Andersen | COO |
Content on BioPorto Diagnostics
You may also be interested in…
- 4SC
- Acacia Pharma
- Acarix
- ADL Bionatur Solutions
- Adocia
- ASIT biotech
- Basilea Pharmaceutica
- Bonesupport
- Brighter
- Cantargia
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- MagForce
- Medigene
- Mologen
- Nanobiotix
- NeuroVive Pharmaceutical
- Newron Pharmaceuticals
- Nuevolution
- Oncology Venture
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Photocure
- Pixium Vision
- Probiodrug
- Quantum Genomics
- Selvita
- Targovax
- Transgene
- TxCell
- Xbrane Biopharma